^
Association details:
| Biomarker: | IL2 elevation |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Ukoniq (umbralisib) (PI3Kδ inhibitor, Casein kinase I epsilon inhibitor) + Briumvi (ublituximab-xiiy) (CD20 inhibitor) + edralbrutinib (TG-1701) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 2205: TG-1701, a novel irreversible Bruton's kinase (BTK) inhibitor, cooperates with ublituximab-driven ADCC and ADCP in in vitro and in vivo models of ibrutinib-resistant mantle cell lymphoma
Published date:
05/15/2020
Excerpt:
...TG-1701 cooperated with the novel anti-CD20 antibody ublituximab and the novel PI3Kδ-CK1ε dual inhibitor umbralisib in reducing the tumor growth in both ibrutinib-sensitive (REC1) and ibrutinib-resistant (UPN-1res) mouse models of MCL. In accordance with in vitro data, the antitumor activity of the drug combination was associated with increased production of IL-2, IL-6 and TNFα,...
DOI:
10.1158/1538-7445.AM2020-2205
